Prevalence and Risk Factors of COVID-19 Symptoms among U.S. Adults with Allergies.
COVID-19
SARS-CoV-2
allergy
coronavirus
Journal
International journal of environmental research and public health
ISSN: 1660-4601
Titre abrégé: Int J Environ Res Public Health
Pays: Switzerland
ID NLM: 101238455
Informations de publication
Date de publication:
24 02 2021
24 02 2021
Historique:
received:
19
12
2020
revised:
16
02
2021
accepted:
18
02
2021
entrez:
6
3
2021
pubmed:
7
3
2021
medline:
13
3
2021
Statut:
epublish
Résumé
This study sought to evaluate COVID-19 associated physical and mental health symptoms among adults with allergies compared to the general U.S. adult population. Data for these analyses were obtained from the publicly available COVID-19 Household Impact Survey, which provides national and regional statistics about physical health, mental health, economic security, and social dynamics among U.S. adults (ages 18 and older). Data from 20-26 April 2020; 4-10 May 2020; and 30 May-8 June 2020 were included. Our primary outcomes for this analysis were physical and mental health symptoms experienced in the last seven days. The primary predictor was participants' self-report of a physician diagnosis of an allergy. This study included 10,760 participants, of whom 44% self-reported having allergies. Adults with allergies were more likely to report physical symptoms compared to adults without allergies including fever (aOR 1.7, 95% CI 1.44-1.99), cough (aOR 1.9, 95% CI 1.60-2.26), shortness of breath (aOR 2.04, 95% CI 1.71-2.43), and loss of taste or sense of smell (aOR 1.9, 95% CI 1.58-2.28). Adults with allergies were more likely to report feeling nervous (cOR 1.34, 95% CI 1.13, 1.60), depressed (cOR 1.32, 95% CI 1.11-1.57), lonely (cOR 1.23, 95% CI 1.04-1.47), hopeless (cOR 1.44, 95% CI 1.21-1.72), or having physical reactions when thinking about COVID-19 pandemic (cOR 2.01, 95% CI 1.44-2.82), compared to those without allergies. During the COVID-19 pandemic, adults with allergies are more likely to report physical and mental health symptoms compared to individuals without allergies. These findings have important implications for diagnostic and treatment challenges for allergy physicians.
Sections du résumé
BACKGROUND
This study sought to evaluate COVID-19 associated physical and mental health symptoms among adults with allergies compared to the general U.S. adult population.
METHODS
Data for these analyses were obtained from the publicly available COVID-19 Household Impact Survey, which provides national and regional statistics about physical health, mental health, economic security, and social dynamics among U.S. adults (ages 18 and older). Data from 20-26 April 2020; 4-10 May 2020; and 30 May-8 June 2020 were included. Our primary outcomes for this analysis were physical and mental health symptoms experienced in the last seven days. The primary predictor was participants' self-report of a physician diagnosis of an allergy.
RESULTS/DISCUSSION
This study included 10,760 participants, of whom 44% self-reported having allergies. Adults with allergies were more likely to report physical symptoms compared to adults without allergies including fever (aOR 1.7, 95% CI 1.44-1.99), cough (aOR 1.9, 95% CI 1.60-2.26), shortness of breath (aOR 2.04, 95% CI 1.71-2.43), and loss of taste or sense of smell (aOR 1.9, 95% CI 1.58-2.28). Adults with allergies were more likely to report feeling nervous (cOR 1.34, 95% CI 1.13, 1.60), depressed (cOR 1.32, 95% CI 1.11-1.57), lonely (cOR 1.23, 95% CI 1.04-1.47), hopeless (cOR 1.44, 95% CI 1.21-1.72), or having physical reactions when thinking about COVID-19 pandemic (cOR 2.01, 95% CI 1.44-2.82), compared to those without allergies. During the COVID-19 pandemic, adults with allergies are more likely to report physical and mental health symptoms compared to individuals without allergies. These findings have important implications for diagnostic and treatment challenges for allergy physicians.
Identifiants
pubmed: 33668246
pii: ijerph18052231
doi: 10.3390/ijerph18052231
pmc: PMC7967666
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Health Equity. 2020 Aug 05;4(1):336-344
pubmed: 32783017
JAMA Intern Med. 2020 Jun 1;180(6):817-818
pubmed: 32275292
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Arch Acad Emerg Med. 2020 Mar 24;8(1):e35
pubmed: 32232218
J Allergy Clin Immunol. 2017 Oct;140(4):909-920
pubmed: 28987220
Psychiatry Res. 2020 Sep;291:113267
pubmed: 32623266
Depress Anxiety. 2020 Oct;37(10):954-956
pubmed: 32667081
Acta Psychiatr Scand. 2020 Sep;142(3):249-256
pubmed: 32716520
Int J Environ Res Public Health. 2020 Mar 06;17(5):
pubmed: 32155789
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
J Allergy Clin Immunol. 2020 Oct;146(4):790-798
pubmed: 32810517
Clin Exp Allergy. 2012 Dec;42(12):1765-71
pubmed: 23181792
Transl Psychiatry. 2020 Jul 31;10(1):263
pubmed: 32737292
Int J Environ Res Public Health. 2020 Jul 08;17(14):
pubmed: 32650522
Am J Respir Crit Care Med. 2014 Dec 15;190(12):1373-82
pubmed: 25350863
Psychosom Med. 2006 Jan-Feb;68(1):94-8
pubmed: 16449417
Psychosomatics. 1999 Nov-Dec;40(6):491-6
pubmed: 10581977
Brain Behav Immun. 2020 Jul;87:40-48
pubmed: 32298802
J Eur Acad Dermatol Venereol. 2019 Mar;33(3):588-594
pubmed: 30468531
JAMA Netw Open. 2020 Jul 1;3(7):e2014053
pubmed: 32609353
JCO Oncol Pract. 2021 Jan 22;:OP2000752
pubmed: 33492984
Ann Thorac Surg. 2016 May;101(5):1644-5
pubmed: 27106412